Pharma

Pharma formulations attract GST of 12 per cent whereas inputs active pharmaceutical ingredients (API) have GST of 18 per cent which has led to accumulation of Input tax Credit.

On the BSE, the Sun Pharma stock jumped as much as 3.15 per cent to Rs 441.00 apiece after the earnings announcement.

Shares in Dr Reddy's Laboratories rose as much as 1.66 per cent to Rs 2,829.00 apiece on the BSE after the earnings announcement by the drug maker.

IICT Hyderabad: The deal is for patents related to certain compounds with potential therapeutic activity across multiple indications in Sun Pharma's specialty focus areas, the Mumbai-based pharmaceuticals company said on Wednesday.

Shares in Sun Pharma jumped as much as 5.43 per cent after the earnings announcement.

Cipla's revenue from its pharmaceuticals business increased 1.22 per cent to Rs 3,959.93 crore in the quarter ended June 30.

The company said its research and development (R&D) expenses stood at Rs 361 crore in the quarter ended June 30.

US FDA had inspected Strides Pharma's drug manufacturing facility in Puducherry from January 28 to February 5, 2019 and said that the company was caught trying to dispose quality-control records.

Aurobindo said it does not anticipate that these matters will have a material impact on the its operations or business results.

Sun Pharma shares price today jumped more than 4 per cent in intraday trade. Sun Pharma the previous day reported a nearly four-fold increase in quarterly net profit. Sun Pharma said it had incurred a one-time tax expense of Rs 513 crore - related to changes in US tax rates - in the year-ago period.

Sun Pharmaceutical Industries' total revenue from operations grew 16.3 per cent to Rs 7740 crore.

CARE has said that the government is expected to proceed with its focus on medicines that are available at affordable prices.

RHT Health Trust, which was originally named Religare Health Trust, netted Fortis about 510 million Singapore dollars when it listed in October 2012.

With the government set to present its Interim Budget on February 1, all eyes are on any announcements for the pharma sector.

The company, currently mired in a controversy surrounding the safety of its baby talcum powder, reported overall sales of Rs 5,828 crore ($829 million) in the country for the year, its filing with the Ministry of Corporate Affairs shows.